NDA 214927 · Zevra Denmark
Miplyffa
Arimoclomol Citrate · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Sep 20, 2024: To treat Niemann-Pick disease type C
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Sep 20, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
6 Phase 3, 0 recruiting
FAERS reports
46
16 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 18, 2026.
MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. ( 1 )
Mechanism: The mechanism(s) by which arimoclomol exerts its clinical effects in patients with NPC is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 20, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
4 products under this application
- MIPLYFFA · ARIMOCLOMOL CITRATE EQ 124MG BASE · CAPSULE, ORAL · Prescription
- MIPLYFFA · ARIMOCLOMOL CITRATE EQ 62MG BASE · CAPSULE, ORAL · Prescription
- MIPLYFFA · ARIMOCLOMOL CITRATE EQ 93MG BASE · CAPSULE, ORAL · Prescription
- MIPLYFFA · ARIMOCLOMOL CITRATE EQ 47MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Arimoclomol" as an intervention, any sponsor and status, largest first.
- Arimoclomol in Amyotropic Lateral SclerosisPivotal-lookingCompleted
ZevraDenmarkIndustry
NCT03491462 · 245 participants · Start Jul 31, 2018 · Primary completion Dec 18, 2020
Drug: Arimoclomol; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Orange, California; Miami, Florida · 29 sites in all
- Study of Arimoclomol in Inclusion Body Myositis (IBM)Pivotal-lookingCompleted
ZevraDenmarkIndustry
NCT02753530 · 152 participants · Start Aug 16, 2017 · Primary completion Jan 11, 2021
Drug: Arimoclomol · For: Inclusion Body Myositis
Sites: Phoenix, Arizona; Irvine, California; Aurora, Colorado · 12 sites in all
- Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension TrialPivotal-lookingTerminated
ZevraDenmarkIndustry
NCT04049097 · 121 participants · Start May 20, 2019 · Primary completion Nov 15, 2021
Drug: Arimoclomol · For: Inclusion Body Myositis
Sites: Phoenix, Arizona; Irvine, California; Aurora, Colorado · 12 sites in all
- Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension TrialPivotal-lookingTerminated
ZevraDenmarkIndustry
NCT03836716 · 120 participants · Start Sep 19, 2019 · Primary completion Jul 2, 2021
Drug: Arimoclomol · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Orange, California; Miami, Florida · 23 sites in all
CytRxIndustry
NCT00244244 · 80 participants · Start Oct 2005 · Primary completion Jan 2007
Drug: arimoclomol · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Irvine, California; Miami, Florida; Kansas City, Kansas · 10 sites in all
- Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type CPivotal-lookingCompleted
ZevraDenmarkIndustry
NCT02612129 · 50 participants · Start Jun 14, 2016 · Primary completion Jun 25, 2018
Drug: arimoclomol; Placebo · For: Niemann-Pick Disease, Type C
Sites: Oakland, California; Rochester, Minnesota; Copenhagen, Denmark · 14 sites in all
ZevraDenmarkIndustry
NCT03746587 · 39 participants · Start Jun 6, 2018 · Primary completion Apr 1, 2020
Drug: Arimoclomol; Placebo oral capsule · For: Gaucher Disease, Type 1; Gaucher Disease, Type 3
Sites: Mumbai, India; Pune, India; New Delhi, India · 8 sites in all
- Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral SclerosisPivotal-lookingCompleted
University of MiamiAcademic, hospital or other
NCT00706147 · 38 participants · Start Jan 2009 · Primary completion Dec 2014
Drug: Arimoclomol; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Miami, Florida; Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea6
- vomiting5
- product size issue4
- insomnia3
- pneumonia aspiration3
- death2
- fall2
- fatigue2
- gait disturbance2
- pneumonia2
- product administration interrupted2
- product distribution issue2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2025 | 39 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Miplyffa (Arimoclomol Citrate)
2024 spending
$1.9M
Beneficiaries
13
18 claims
Per beneficiary
$143,884
$1,199.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,870,497 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
Mengel E, Patterson MC, Da Riol RM, et al. · J Inherit Metab Dis 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM, McDermott MP, Blaettler T, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Multicenter Study
- Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, et al. · Lancet Neurol 2024 · Randomized Controlled Trial, Multicenter Study
- Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.
Benatar M, Wuu J, Andersen PM, et al. · Neurology 2018 · Multicenter Study, Randomized Controlled Trial
- Safety and efficacy of arimoclomol in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Masood S, Almas MS, Hassan SSU, et al. · Neurol Sci 2025 · Systematic Review, Meta-Analysis
- Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial.
Mengel E, Da Riol RM, Del Toro M, et al. · Mol Genet Metab 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Zevra Denmark
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.